Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Annika M. Frank"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 28, Iss , Pp 90-98 (2023)
CD3-targeted lentiviral vectors (CD3-LVs) mediate selective transduction of human T lymphocytes in vitro and in vivo while simultaneously activating the targeted cells. Previously, we have demonstrated that CD3-LV leads to downmodulation of the CD3:T
Externí odkaz:
https://doaj.org/article/533d5df46b0644b98f2c55edb54119fe
Autor:
Laura Kapitza, Naphang Ho, Thomas Kerzel, Annika M. Frank, Frederic B. Thalheimer, Arezoo Jamali, Thomas Schaser, Christian J. Buchholz, Jessica Hartmann
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Chimeric antigen receptor (CAR)-expressing T cells are a complex and heterogeneous gene therapy product with variable phenotype compositions. A higher proportion of less differentiated CAR T cells is usually associated with improved antitumoral funct
Externí odkaz:
https://doaj.org/article/d16778f7ed9243059db65c4e58de6741
Autor:
Alexander Michels, Annika M. Frank, Dorothee M. Günther, Mehryad Mataei, Kathleen Börner, Dirk Grimm, Jessica Hartmann, Christian J. Buchholz
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss , Pp 334-347 (2021)
Preclinical studies on gene delivery into mouse lymphocytes are often hampered by insufficient activity of lentiviral (LV) and adeno-associated vectors (AAVs) as well as missing tools for cell type selectivity when considering in vivo gene therapy. H
Externí odkaz:
https://doaj.org/article/af713ec8eb904a748c49f07e9595bc48
Autor:
Annika M. Frank, Christian J. Buchholz
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss , Pp 19-31 (2019)
Lymphocytes have always been among the prime targets in gene therapy, even more so since chimeric antigen receptor (CAR) T cells have reached the clinic. However, other gene therapeutic approaches hold great promise as well. The first part of this re
Externí odkaz:
https://doaj.org/article/9d7c29c7e9c9498e98ae537f22b45eb4
Publikováno v:
Molecular therapy. Methodsclinical development. 28
CD3-targeted lentiviral vectors (CD3-LVs) mediate selective transduction of human T lymphocytes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe792cbe770dc9e21054b0c37603b7a7
https://pubmed.ncbi.nlm.nih.gov/36620073
https://pubmed.ncbi.nlm.nih.gov/36620073
Autor:
Julia D. S. Hanauer, Shiwani Agarwal, Annika M. Frank, Frederic B. Thalheimer, Vanessa Riechert, Christian J. Buchholz
Publikováno v:
Molecular Therapy. 28:1783-1794
T cells modified with CD19-specific chimeric antigen receptors (CARs) result in significant clinical benefit for leukemia patients but constitute a challenge for manufacturing. We have recently demonstrated the in vivo generation of CD19-CAR T cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::613bf83411a3dacbf5aa08bea430465f
https://doi.org/10.1016/j.ymthe.2020.05.005
https://doi.org/10.1016/j.ymthe.2020.05.005
Autor:
Tatjana Weidner, Jessica Hartmann, Annika M. Frank, Christian J. Buchholz, Julia Brynza, Wolfgang Uckert
Publikováno v:
Human Gene Therapy. 31:679-691
Adoptive T cell immunotherapy in combination with gene therapy is a promising treatment concept for chronic infections and cancer. Recently, receptor-targeted lentiviral vectors (LVs) were shown to enable selective gene transfer into particular types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd89e510e4fb194b27cf13b3f13b8e5a
https://doi.org/10.1089/hum.2019.248
https://doi.org/10.1089/hum.2019.248
Autor:
Christian J. Buchholz, Jessica Hartmann, Kathleen Börner, Dorothee M. Günther, Dirk Grimm, Annika M. Frank, Alexander Michels, Mehryad Mataei
Publikováno v:
Mol Ther Methods Clin Dev
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss, Pp 334-347 (2021)
Molecular therapy, 23:334-347
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss, Pp 334-347 (2021)
Molecular therapy, 23:334-347
Molecular Therapy. Methods & Clinical Development
Preclinical studies on gene delivery into mouse lymphocytes are often hampered by insufficient activity of lentiviral (LV) and adeno-associated vectors (AAVs) as well as missing tools for cell type selectivity when considering in vivo gene therapy. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd69f9cfa4870088d63bc2fe2cbdb3d5
https://hdl.handle.net/21.11116/0000-000C-795A-821.11116/0000-0009-D149-9
https://hdl.handle.net/21.11116/0000-000C-795A-821.11116/0000-0009-D149-9
Autor:
Shiwani, Agarwal, Julia D S, Hanauer, Annika M, Frank, Vanessa, Riechert, Frederic B, Thalheimer, Christian J, Buchholz
Publikováno v:
Mol Ther
T cells modified with CD19-specific chimeric antigen receptors (CARs) result in significant clinical benefit for leukemia patients but constitute a challenge for manufacturing. We have recently demonstrated the in vivo generation of CD19-CAR T cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03f20714bc2e9d576691a59d90af3fdf
https://pubmed.ncbi.nlm.nih.gov/32485137
https://pubmed.ncbi.nlm.nih.gov/32485137
Autor:
Christian J. Buchholz, Annika M. Frank
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss, Pp 19-31 (2019)
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss, Pp 19-31 (2019)
Lymphocytes have always been among the prime targets in gene therapy, even more so since chimeric antigen receptor (CAR) T cells have reached the clinic. However, other gene therapeutic approaches hold great promise as well. The first part of this re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02690d1ec1d62637445af2a3b5f4f4e2
http://europepmc.org/articles/PMC6216101
http://europepmc.org/articles/PMC6216101